We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
IDEXX Laboratories (IDXX) Beats on Q4 Revenues, View Up
Read MoreHide Full Article
Headquartered in Delaware NJ, IDEXX Laboratories, Inc. (IDXX - Free Report) is a developer, manufacturer and distributer of products and services primarily for the companion animal veterinary, livestock and poultry, water testing and dairy markets. The company also sells a series of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.
Currently, IDEXX has a Zacks Rank #2 (Buy) but that could change following its mixed fourth-quarter 2017 earnings report whichhas just released. (You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here). We have highlighted some of the key details from the just-released announcement below:
Earnings: The current Zacks Consensus Estimate is pegged at 73 cents per share. IDEXX’s fourth-quarter reported earnings per share came in at 43 cents, a decrease of 26% year-over-year. Moreover, excluding negative impact of 34 cents per share due to U.S tax reform and a 7 cents per share benefit from other tax items, the adjusted earnings came in at 70 cents. The adjusted figure missed the Zacks Consensus Estimate by 3 cents.
Revenues: IDEXX posted revenues of almost $506.1 million, an increase of 14% year over year, which has beat the Zacks Consensus Estimate for revenues of $491 million by 3.1%.
Key Stats: Among its four business segments, IDEXX delivered fourth-quarter revenues of $433.5 million (up 14%) in CAG, $28.9 million (up 19%) in Water, $ 37.2 million (up 13%) Livestock, Poultry and Dairy (LPD) and $6.5 million (up 6.6%) in the other segment.
Major Factors: Per management, growth in business fourth quarter is majorly driven by strength in the CAG revenue segment. Furthermore, the premium instrument placements including a 25% year over year increase in Catalyst placements in the reported quarter has yielded solid returns as well.
Coming to the guidance, the company has updated the 2018 revenue growth guidance to 12% - 14% on a reported basis and 9.5% - 11.5% on an organic basis. The company raised the full year adjusted earnings to the range of $4.04 - $4.18.
Stock Price: Following the earnings release, share prices did not show any movement in the pre-market trading session.
Check back later for our full write up on this IDEXX earnings report later!
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Image: Bigstock
IDEXX Laboratories (IDXX) Beats on Q4 Revenues, View Up
Headquartered in Delaware NJ, IDEXX Laboratories, Inc. (IDXX - Free Report) is a developer, manufacturer and distributer of products and services primarily for the companion animal veterinary, livestock and poultry, water testing and dairy markets. The company also sells a series of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.
Currently, IDEXX has a Zacks Rank #2 (Buy) but that could change following its mixed fourth-quarter 2017 earnings report whichhas just released. (You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here). We have highlighted some of the key details from the just-released announcement below:
Earnings: The current Zacks Consensus Estimate is pegged at 73 cents per share. IDEXX’s fourth-quarter reported earnings per share came in at 43 cents, a decrease of 26% year-over-year. Moreover, excluding negative impact of 34 cents per share due to U.S tax reform and a 7 cents per share benefit from other tax items, the adjusted earnings came in at 70 cents. The adjusted figure missed the Zacks Consensus Estimate by 3 cents.
Revenues: IDEXX posted revenues of almost $506.1 million, an increase of 14% year over year, which has beat the Zacks Consensus Estimate for revenues of $491 million by 3.1%.
Key Stats: Among its four business segments, IDEXX delivered fourth-quarter revenues of $433.5 million (up 14%) in CAG, $28.9 million (up 19%) in Water, $ 37.2 million (up 13%) Livestock, Poultry and Dairy (LPD) and $6.5 million (up 6.6%) in the other segment.
Major Factors: Per management, growth in business fourth quarter is majorly driven by strength in the CAG revenue segment. Furthermore, the premium instrument placements including a 25% year over year increase in Catalyst placements in the reported quarter has yielded solid returns as well.
IDEXX Laboratories, Inc. Price and EPS Surprise
IDEXX Laboratories, Inc. Price and EPS Surprise | IDEXX Laboratories, Inc. Quote
Coming to the guidance, the company has updated the 2018 revenue growth guidance to 12% - 14% on a reported basis and 9.5% - 11.5% on an organic basis. The company raised the full year adjusted earnings to the range of $4.04 - $4.18.
Stock Price: Following the earnings release, share prices did not show any movement in the pre-market trading session.
Check back later for our full write up on this IDEXX earnings report later!
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>